Envíe este artículo por correo electrónico (Inicie sesión)
Enviar un correo electrónico al autor/a (Inicie sesión) Open Journal Systems
Epidemiología reportada de cáncer de labio, cavidad oral y orofaringe en México / Reported epidemiology of cancer of the lip, oral cavity and oropharynx in Mexico
Resumen
Resumen
En 2008, la Organización Mundial de la Salud (OMS) reportó que el 13% de las muertes a nivel mundial estuvieron relacionadas a cáncer. Debido a su magnitud es un problema prioritario de salud pública del cual se requiere información epidemiológica suficiente para optimizar programas nacionales de salud. Por lo tanto, el objetivo de esta revisión de la literatura es describir los tipos de cáncer más comunes de labio, cavidad oral y orofaringe, reportados en la población mexicana. Se realizó una revisión sistemática siguiendo los lineamientos PRISMA; la información disponible se compiló de las bases de datos electrónicas PubMed, Google Académico y Science Direct, así como de las bases abiertas de datos de salud a nivel nacional. La búsqueda electrónica se realizó con las siguientes palabras clave en inglés “(oral cancer OR oral neoplasm) AND (Mexico) AND (epidemiology OR prevalence)”, y sus equivalentes en español.
Abstract
In 2008 the World Health Organization reported that 13% of worldwide deaths were related to cancer. Due to its magnitude, this pathology has become a central public health problem. Therefore epidemiological information at national level is required to optimize health care programs. The aim of this review is to describe the most common types of cancer in lips, oral cavity, and oropharynx reported in Mexican population. A systematic review was carried out following PRISMA guidelines; information was compiled from electronic databases PubMed, Google Scholar and Science Direct, as well as from open Mexican health databases. Electronic search was performed using following Medical Subject Headings, MeSH terms “(oral cancer OR oral neoplasm) AND (Mexico) AND (epidemiology OR prevalence)” and the equivalent keywords in Spanish.
Palabras clave
Referencias
1. World Health Organization. Global status report on noncommunicable diseases. 1st ed. Switzerland; WHO-press: 2010. Disponible en: https://www.who.int/nmh/publications/ncd_report2010/en/
2. World Health Organization. Noncommunicable diseases country profiles 2018. 1st ed. 2018. 223 p. Disponible en: https://www.who.int/nmh/publications/ncd-profiles-2018/en/
3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. Disponible en: https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21492
4. Cancer Facts. World Health Organization. Cancer. Key Statistics. Disponible en: https://www.who.int/cancer/resources/keyfacts/en/. Fecha de consulta: 5 de junio de 2019.
5. Forouzanfar MH, Afshin A, Alexander LT, Anderson HR, Bhutta ZA, Biryukov S, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1659–724. Disponible en: https://www.sciencedirect.com/science/article/pii/S0140673616316798
6. La Rosa GRM, Gattuso G, Pedullà E, Rapisarda E, Nicolosi D, Salmeri M. Association of oral dysbiosis with oral cancer development. Oncol Lett. 2020;19(4):3045–58. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079586/pdf/ol-19-04-3045.pdf
7. Börnigen D, Ren B, Pickard R, Li J, Ozer E, Hartmann EM, et al. Alterations in oral bacterial communities are associated with risk factors for oral and oropharyngeal cancer. Sci Rep. 2017;7(1):1–13. Disponible en: https://www.nature.com/articles/s41598-017-17795-z
8. Ustrell-Borràs M, Traboulsi-Garet B, Gay-Escoda C. Alcohol-based mouthwash as a risk factor of oral cancer: A systematic review. Med Oral Patol Oral Cir Bucal. 2020;25(1):e1. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6982979/pdf/medoral-25-e1.pdf
9. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J cancer. 2015;136(5):E359–86. Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.29210
10. Kachuri L, De P, Ellison LF, Semenciw R. Cancer incidence, mortality and survival trends in Canada, 1970-2007. Chronic Dis Inj Can. 2013;33(2). Disponible en: https://www.canada.ca/content/dam/phac-aspc/migration/phac-aspc/publicat/hpcdp-pspmc/33- 2/assets/pdf/CDIC_MCC_Vol33_2_3_Kachuri_E_69.pdf
11. Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med, 2009;151(4), 264-269. Disponible en: https://annals.org/aim/fullarticle/744664/preferred-reporting-items-systematic- reviews-meta-analyses-prisma-statement
12. Luna-Ortiz K, Güemes-Meza A, Villavicencio-Valencia V, Mosqueda-Taylor A. Upper lip malignant neoplasms. A study of 59 cases. Med Oral Patol Oral Cir Bucal. 2012;17(3):e371. Disponible en: http://www.medicinaoral.com/pubmed/medoralv17_i3_p371.pdf
13. Luna-Ortiz K, Güemes-Meza A, Villavicencio-Valencia V, Mosqueda-Taylor A. Lip cancer experience in Mexico. An 11-year retrospective study. Oral Oncol. 2004;40(10):992–9. doi: https://doi.org/10.1016/j.oraloncology.2004.04.013
14. Hernández-Guerrero J-C, Jiménez-Farfán M-D, Jacinto-Alemán L-F, Macario-Hernández A, Alcántara-Vázquez A, de la Fuente-Hernandez J. P95. Oral squamous cell carcinoma experience in a high concentration hospital of Mexico city. A 18 years retrospective study. Oral Oncol. 2011;1(47):S104. doi: http://dx.doi.org/10.1016%2Fj.oraloncology.2011.06.338
15. Hernández-Guerrero JC, Jacinto-Alemán LF, Jiménez-Farfán MD, Macario-Hernández A, Hernández-Flores F, Alcántara-Vázquez A. Prevalence trends of oral squamous cell carcinoma. Mexico City’s General Hospital experience. Med Oral Patol Oral Cir Bucal. 2013;18(2):e306. Disponible en: http://www.medicinaoral.com/pubmed/medoralv18_i2_p306.pdf
16. Secretaría de Salud, Subsecretaría de Prevención y Promoción de la Salud, Dirección General de Epidemiología. Perfil epidemiológico de los tumores malignos en México. México, D.F.: Secretaria de Salud; 2011. Disponible en: https://epidemiologiatlax.files.wordpress.com/2012/10/p_epi_de_los_tumores_malignos_mc3a9 xico.pdf
17. Registro de pacientes de nuevo ingreso del Instituto Nacional de Cancerología [Internet]. Datos obtenidos de la Base de Datos Abiertos de Salud en México. [cited 2019 Feb 3]. Disponible en: https://datos.gob.mx/busca/dataset?theme=Salud
18. Mosqueda-Taylor A, Ledesma-Montes C, Caballero-Sandoval S, Portilla-Robertson J, Rivera LMR-G, Meneses-García A. Odontogenic tumors in Mexico: a collaborative retrospective study of 349 cases. Oral Surgery, Oral Med Oral Pathol Oral Radiol Endodontology. 1997;84(6):672–5. Disponible en: https://www.oooojournal.net/article/S1079-2104(97)90371-1/pdf
19. Mohar A, Frías-Mendivil M, Suchil-Bernal L, Mora-Macías T, Garza JG. Epidemiología descriptiva de cáncer en el Instituto Nacional de Cancerología de México. Salud Publica Mex. 1997;39:253–8. Disponible en: https://www.redalyc.org/pdf/106/10639402.pdf
20. Meza García G, Muñoz Ibarra JJ, Páez Valencia C, Cruz Legorreta B, Aldape Barrios B. Carcinoma de células escamosas de cavidad bucal en un centro de tercer nivel de atención social en la ciudad de México: Experiencia de cinco años. Av Odontoestomatol. 2009;25(1):19–28. Disponible en: http://scielo.isciii.es/pdf/odonto/v25n1/original2.pdf
21. Gaitán-Cepeda L-A, Peniche-Becerra A-G, Quezada-Rivera D. Trends in frequency and prevalence of oral cancer and oral squamous cell carcinoma in Mexicans. A 20 years retrospective study. Med Oral Patol Oral Cir Bucal. 2011;16(1):e1-5. doi:10.4317/medoral.16.e1.
22. Moctezuma-Bravo GS, de León-Medina RD, Rodríguez-Quilantan FJ, Moctezuma-Dávila M. Cáncer oral en un hospital general de zona del Instituto Mexicano del Seguro Social en Mèxico,(1988-2005). Gac Mex Oncol. 2015;14(6):323–8. Disponible en: https://www.sciencedirect.com/science/article/pii/S1665920115001170
23. Schutte HW, Heutink F, Wellenstein DJ, van den Broek GB, van den Hoogen FJA, Marres HAM, et al. Impact of Time to Diagnosis and Treatment in Head and Neck Cancer: A Systematic Review. Otolaryngol Neck Surg. 2020;162(4):446–57. doi: 10.1177/0194599820906387.
24. Gómez I, Seoane J, Varela‐Centelles P, Diz P, Takkouche B. Is diagnostic delay related to advanced‐stage oral cancer? A meta‐analysis. Eur J Oral Sci. 2009;117(5):541–6. doi: 10.1111/j.1600-0722.2009.00672.x.
25. Carreras-Torras C, Gay-Escoda C. Techniques for early diagnosis of oral squamous cell carcinoma: Systematic review. Med Oral Patol Oral Cir Bucal. 2015;20(3):e305. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4464918/pdf/medoral-20-e305.pdf
26. Chen S, Forman M, Sadow PM, August M. The diagnostic accuracy of incisional biopsy in the oral cavity. J Oral Maxillofac Surg. 2016;74(5):959–64. doi: 10.1016/j.joms.2015.11.006.
27. Arakeri G, Patil SG, Aljabab AS, Lin K, Merkx MAW, Gao S, et al. Oral submucous fibrosis: an update on pathophysiology of malignant transformation. J Oral Pathol Med. 2017;46(6):413– 7. doi: 10.1111/jop.12582.
28. Khan Z, Khan S, Christianson L, Rehman S, Ekwunife O, Samkange-Zeeb F. Smokeless tobacco and oral potentially malignant disorders in South Asia: a systematic review and meta- analysis. Nicotine Tob Res. 2017;20(1):12–21. doi: 10.1093/ntr/ntw310.
29. Parakh MK, Ulaganambi S, Ashifa N, Premkumar R, Jain AL. Oral potentially malignant disorders: clinical diagnosis and current screening aids: a narrative review. Eur J Cancer Prev. 2020;29(1):65–72. doi: 10.1097/CEJ.0000000000000510.
30. Kaur J, Jacobs R, Huang Y, Salvo N, Politis C. Salivary biomarkers for oral cancer and pre- cancer screening: a review. Clin Oral Investig. 2018;22(2):633–40. doi: 10.1007/s00784-018- 2337-x
31. Liu D, Zhao X, Zeng X, Dan H, Chen Q. Non-invasive techniques for detection and diagnosis of oral potentially malignant disorders. Tohoku J Exp Med. 2016;238(2):165–77. Disponible en: https://www.jstage.jst.go.jp/article/tjem/238/2/238_165/_pdf/-char/en
32. Lingen MW, Kalmar JR, Karrison T, Speight PM. Critical evaluation of diagnostic aids for the detection of oral cancer. Oral Oncol. 2008;44(1):10–22. doi: 10.1016/j.oraloncology.2007.06.011.
33. Vijayakumar V, Reghunathan D, Edacheriyan B, Mukundan A. Role of Toluidine Blue Staining in Suspicious Lesions of Oral Cavity and Oropharynx. Indian J Otolaryngol Head Neck Surg. 2019;1–5. doi: 10.1007/s12070-017-1161-y.
34. Casparis S, Borm JM, Tomic MA, Burkhardt A, Locher MC. Transepithelial Brush Biopsy– Oral CDx®–A Noninvasive Method for the Early Detection of Precancerous and Cancerous Lesions. J Clin Diagnostic Res JCDR. 2014;8(2):222. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3972569/pdf/jcdr-8-222.pdf
35. Deuerling L, Gaida K, Neumann H, Remmerbach TW. Evaluation of the Accuracy of Liquid- Based Oral Brush Cytology in Screening for Oral Squamous Cell Carcinoma. Cancers. 2019;11(11):1813. Disponible en: https://www.mdpi.com/2072-6694/11/11/1813/htm
36. H. Alsarraf A, Kujan O, Farah CS. The utility of oral brush cytology in the early detection of oral cancer and oral potentially malignant disorders: a systematic review. J Oral Pathol Med. 2018;47(2):104–16. doi: 10.1111/jop.12660.
37. Chen P-H, Chen Y-J, Chen Y-F, Yeh Y-C, Chang K-W, Hou M-C, et al. Quantification of structural and microvascular changes for diagnosing early-stage oral cancer. Biomed Opt Express. 2020;11(3):1244–56. Disponible en: https://www.osapublishing.org/DirectPDFAccess/4F95DD86-3BA0-48F9- AC68ED7F10F8D01A_426506/boe-11-3-1244.pdf?da=1&id=426506&seq=0&mobile=no
38. Wu H-L, Guan B-X, Liu B, Wang H-J, Zhang M-B, Li G-C, et al. The intrapapillary capillary loop (IPCL) changes in superficial esophageal lesions. Dis Esophagus. 2017;30(1). doi: 10.1111/dote.12476
39. Sawan D, Mashlah A. Evaluation of premalignant and malignant lesions by fluorescent light (VELscope). J Int Soc Prev Community Dent. 2015;5(3):248. Disponible en: http://www.jispcd.org/article.asp?issn=2231- 0762;year=2015;volume=5;issue=3;spage=248;epage=254;aulast=Sawan
40. Nagi R, Reddy-Kantharaj Y-B, Rakesh N, Janardhan-Reddy S, Sahu S. Efficacy of light based detection systems for early detection of oral cancer and oral potentially malignant disorders: systematic review. Med Oral Patol Oral Cir Bucal. 2016;21(4):e447. Disponible en: http://www.medicinaoral.com/pubmed/medoralv21_i4_p447.pdf
41. Macey R, Walsh T, Brocklehurst P, Kerr AR, Liu JLY, Lingen MW, et al. Diagnostic tests for oral cancer and potentially malignant disorders in patients presenting with clinically evident lesions. Cochrane Database Syst Rev. 2015;(5):1-28. Disponible en: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010276.pub2/full
42. Herrera-Gómez F, García-Mingo M, Álvarez FJ. Benzodiazepines in the oral fluid of Spanish drivers. Subst Abuse Treat Prev Policy. 2020;15(1):1–8. Disponible en: https://substanceabusepolicy.biomedcentral.com/track/pdf/10.1186/s13011-020-00260-y
43. Zhao J, Huang Y. Salivary uric acid as a noninvasive biomarker for monitoring the efficacy of urate-lowering therapy in a patient with chronic gouty arthropathy. Clin Chim Acta. 2015;450:115–20. doi: 10.1016/j.cca.2015.08.005
44. Azzi L, Carcano G, Gianfagna F, Grossi P, Dalla Gasperina D, Genoni A, et al. Saliva is a reliable tool to detect sars-CoV-2. J Infect. 2020;[de próxima aparición] Disponible en: https://reader.elsevier.com/reader/sd/pii/S0163445320302139?token=5BBA1E6422374988DD4 0E2EB87129DEA5FA9481C73CBB213C6122F420C1FECF94829473916A225DEE21DF06B47 9D9A5B
45. Sabalza M, Yasmin R, Barber CA, Castro T, Malamud D, Kim BJ, et al. Detection of Zika virus using reverse-transcription LAMP coupled with reverse dot blot analysis in saliva. PLoS One. 2018;13(2):e0192398. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5798782/pdf/pone.0192398.pdf
46. Ghallab NA, Shaker OG. Serum and salivary levels of chemerin and MMP-9 in oral squamous cell carcinoma and oral premalignant lesions. Clin Oral Investig. 2017;21(3):937–47. doi: 10.1007/s00784-016-1846-8.
47. AlAli AM, Walsh T, Maranzano M. CYFRA 21-1 and MMP-9 as salivary biomarkers for the detection of oral squamous cell carcinoma: a systematic review of diagnostic test accuracy. Int J Oral Maxillofac Surg. 2020;[de próxima aparición]. doi: 10.1002/hed.26140.
48. Pandey S, Osman TA, Sharma S, Vallenari EM, Shahdadfar A, Pun CB, et al. Loss of S100A14 expression at the tumor‐invading front correlates with poor differentiation and worse prognosis in oral squamous cell carcinoma. Head Neck. 2020;1-11[de próxima aparición]. Disponible en: https://onlinelibrary.wiley.com/doi/pdf/10.1002/hed.26140
49. Michailidou E, Tzimagiorgis G, Chatzopoulou F, Vahtsevanos K, Antoniadis K, Kouidou S, et al. Salivary mRNA markers having the potential to detect oral squamous cell carcinoma segregated from oral leukoplakia with dysplasia. Cancer Epidemiol. 2016;43:112–8. doi: 10.1016/j.canep.2016.04.011.
50. Assad DX, Mascarenhas ECP, de Lima CL, de Toledo IP, Chardin H, Combes A, et al. Salivary metabolites to detect patients with cancer: a systematic review. Int J Clin Oncol. 2020;1–21[de próxima aparición]. doi: 10.1007/s10147-020-01660-7.
51. Aldaco-Sarvide F, Pérez-Pérez P, Cervantes-Sánchez G, Torrecillas-Torres L, Erazo-Valle- Solís AA, Cabrera-Galeana P, et al. Mortalidad por cáncer en México: actualización 2015. Cancer. 2018;85:1. doi: 10.24875/j.gamo.M18000105.
52. Herrero R, Castellsagué X, Pawlita M, Lissowska J, Kee F, Balaram P, et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst. 2003;95(23):1772–83. doi:10.1093/jnci/djg107
53. Takahashi Y, Park J, Hosomi K, Yamada T, Kobayashi A, Yamaguchi Y, et al. Analysis of oral microbiota in Japanese oral cancer patients using 16S rRNA sequencing. J oral Biosci. 2019. doi:10.1016/j.job.2019.03.003
54. García-Martín JM, Varela-Centelles P, González M, Seoane-Romero JM, Seoane J, García- Pola MJ. Epidemiology of Oral Cancer. In: Oral Cancer Detection. Springer; 2019. p. 81–93. doi: 10.1007/978-3-319-61255-3_3.
55. Moore SR, Johnson NW, Pierce AM, Wilson DF. The epidemiology of lip cancer: a review of global incidence and aetiology. Oral Dis. 1999;5(3):185–95. doi: 10.1111/j.1601- 0825.1999.tb00300.x.
56. Ant A, Kilic C, Baltu Y, Duran AB, Tunccan T, Ozlugedik S, et al. Lip cancer: Reconsidering the at‐risk patients with pathological assessment. Oral Dis. 2019;25(3):742–9. doi: 10.1111/odi.13017.
57. Cabral R del CR. Epidemiologic behavior and histopathologic variants of skin cancer in Institute of Social Security and Services of State Workers beneficiaries from the State of Nuevo Leon, Mexico. J Am Acad Dermatol. 2018;79(3).
58. López FJ, Tovar V, Barquera S. Tendencias de mortalidad por cánceres atribuibles al tabaco en México. Salud Publica Mex. 2002;44(1). Disponible en: https://www.scielosp.org/article/spm/2002.v44suppl1/s20-s28/
59. Anaya‐Saavedra G, Ramírez‐Amador V, Irigoyen‐Camacho ME, Zimbrón‐Romero A, Zepeda‐Zepeda MA. Oral and pharyngeal cancer mortality rates in Mexico, 1979–2003. J oral Pathol Med. 2008;37(1):11–7. doi: 10.1111/j.1600-0714.2007.00562.x
60. Ramirez-Amador V, Esquivel-Pedraza L, Ochoa-Carrillo FJ, Cuapio-Ortiz A, Frias-Mendivil M, Meneses-Garcia A, et al. Cancer of the mobile tongue in Mexico. A retrospective study of 170 patients. Eur J Cancer Part B Oral Oncol. 1995;31(1):37–40. doi: 10.1016/0964-1955(94)00024- X
61. Granados-García M. Oropharyngeal cancer: an emergent disease? Salud Publica Mex. 2016;58:285–90. Disponible en: https://www.scielosp.org/article/spm/2016.v58n2/285-290/en/
62. de Santillana-Hernández SP, García-Flores MT, Galván-Oseguera H, Pérez-Rodríguez G, Martínez-Chapa HD. Diagnóstico situacional de la atención oncológica en el Instituto Mexicano del Seguro Social. Rev Med Inst Mex Seguro Soc. 2017;55(3):222–330. Disponible en: https://www.redalyc.org/articulo.oa?id=457753492003
63. Speight PM, Palmer S, Moles DR, et al. The cost-effectiveness of screening for oral cancer in primary care. Health Technol Assess 2006; 10: 1-144, iii-iv. 2006/05/19. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK62240/?report=reader
64. Rubio Monteverde H, Rubio Monteverde TM, Álvarez Cordero R. Impacto de las políticas antitabaco en México. Rev La Fac Med. 2011;54(5):22–33. Disponible en: https://www.medigraphic.com/pdfs/facmed/un-2011/un115d.pdf
Enlaces refback
- No hay ningún enlace refback.